US · Healthcare · Medical Devices
EPS came in at -0.18 against a street estimate of -0.19 — a beat of 5.3%.
Analysts rate Neuropace Inc a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $20.00.
| Fund | Stake |
|---|---|
| Polar Capital Holdings PLC | 9.61% |
| Soleus Capital Management, L.P. | 8.48% |
| First Light Asset Management, LLC | 8.34% |
| Morgan Stanley - Brokerage Accounts | 7.73% |
| BlackRock Inc | 7.22% |
| Orbimed Advisors LLC | 4.38% |
| Driehaus Capital Management LLC | 4.22% |
| Vanguard Capital Management, LLC | 3.57% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Neuropace Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.